Sponsored Content

Nucleotides and Alzheimer’s disease: the latest study

Prosol announced the promising result of a first study on the role of dietary nucleotides (RiboDIET®) in Alzheimer's disease: the study showed extremely interesting benefits of a yeast extract high in bioavailable nucleotides in alleviating memory decline, neuroinflammation and oxidative stress in a murine model.

Understanding Alzheimer's disease

Alzheimer's disease is one of the most common forms of dementia, characterised by the deposition of extracellular amyloid-β (Aβ) peptides in the brain. The neuronal death that characterises this neurodegenerative disorder causes irreversible cognitive impairment and behavioural alteration.

The role of natural products and nutraceuticals

The option of natural-derived products and nutraceuticals is scientifically solid and to be considered for a future medical option in industrialised countries. Natural products are not an alternative to drugs but, on the contrary, can be helpful to complement the pharmacological therapy and prevent the onset of chronic diseases.

In this context, it has been shown that ribonucleotides are able to improve the clinical outcomes in immunosuppressive and inflammatory-based diseases.

Scientific investigations on ribonucleotides for Alzheimer's disease

A recent study [1] evaluated the effects of a ribonucleotides-based ingredient (RiboDIET®) in a non-genetic mouse model of Alzheimer's disease. Given the strict involvement of nucleosides and nucleotides in neuronal and cognitive functions, the study team [2] decided to examine whether a ribonucleotides-based ingredient could ameliorate Aβ-induced neuroinflammation and oxidative stress.

Results of the study

The study presented the first complete overview of how the supplementation with a ribonucleotide-based ingredient (RiboDIET®) may have a positive impact on synaptic degeneration in Alzheimer's disease and in controlling the most common form of neurodegenerative disease. In particular, the study showed that:

• RiboDIET® lessens oxidative stress and brain inflammation
• RiboDIET® modulates amyloid pathology in a murine model of Alzheimer's disease
• Ribonucleotide-based ingredients are effective in neuro-inflammatory-based diseases

These results lay the first pillar for the rational use of ribonucleotide-based ingredients for the treatment of Alzheimer's disease and other age-related diseases.

Important note: This study was conducted in a murine (mouse) model. Human clinical trials are needed to confirm whether these findings translate to human patients with Alzheimer's disease.

References

[1] Saviano, A., Casillo, G.M., Rauccia, F., Pernice, A., Santarcangelo, C., Piccolo, M., Ferraro, M.G., Ciccone, M., Sgherbini, A., Pedretti, N., Bonvicini, D., Irace, C., Daglia, M., Mascolo, N., & Maione, F. (2021). Supplementation with ribonucleotide-based ingredient (Ribodiet®) lessens oxidative stress, brain inflammation, and amyloid pathology in a murine model of Alzheimer. Biomedicine & Pharmacotherapy, 139, 111579.

[2] Study team: Anella Saviano, GianMarco Casillo, Federica Rauccia, Alessia Pernice, Cristina Santarcangelo, Marialuisa Piccolo, MariaGrazia Ferraro, Miriam Ciccone, Alessandro Sgherbini, Nadia Pedretti, Daniele Bonvicini, Carlo Irace, Maria Daglia, Nicola Mascolo, Francesco Maione.

Read More